Compass Pathways: A Psychedelics Story
2026-05-29 06:40:36 ET
ADSs of psilocybin therapy concern COMPASS Pathways plc ( CMPS ) have rallied roughly 70% since President Trump signed an executive order accelerating the development of and access to psychedelic drugs. The company looks poised to complete a rolling NDA submission for its COMP360 as a therapy for treatment-resistant depression by 4Q26, opening up an indication with ~4 million Americans. With two February 2026 fundings providing enough cash to get COMP360 to commercialization and sell-side analysts predicting blockbuster status by 2030, COMPASS merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Compass Pathways: A Psychedelics Story
NASDAQ: JNJ
JNJ Trading
0.28% G/L:
$224.075 Last:
2,615,594 Volume:
$222.45 Open:
